Rescheduling Hydrocodone Combination Products Will Lead to More Responsible Use

Published Online: Monday, January 27, 2014
Follow Pharmacy_Times:
In this video, Mary Lynn McPherson, PharmD, professor and vice chair at the University of Maryland School of Pharmacy, argues that rescheduling hydrocodone combination products as Schedule II drugs will introduce limitations that will lead to more responsible prescribing of the drugs and monitoring of their use.
 
This is the ninth in a series of videos in which Dr. McPherson argues in favor of categorizing hydrocodone combination products as Schedule II drugs, and Jeff Fudin, PharmD, argues against doing so. (Drs. McPherson and Fudin were assigned to take these positions for a session at the American Society of Health-System Pharmacists 2013 Midyear Clinical Meeting in Orlando, and their arguments do not necessarily reflect their personal positions on the issue.)
 
These videos were filmed at the ASHP 2013 Midyear Clinical Meeting in Orlando.

Related Articles
John Moorman, PharmD, BCPS, Pharmacist at Akron General Medical Center in Ohio discusses the Provider Status Movement in Ohio.
John Moorman, PharmD, BCPS, Pharmacist at Akron General Medical Center in Ohio talks about the outcome metrics of care transitions that pharmacists should pay attention to.
John Moorman, PharmD, BCPS, talks about changes in pharmacy practice to improve patient adherence to diabetes drugs as they move through transitions of care settings.
John Moorman, PharmD, BCPS, Pharmacist at Akron General Medical Center in Ohio discusses the unmet needs of endocrine disorders that pharmacists fulfills during care transitions.
Latest Issues
$auto_registration$